DENDRITIC CELL-BASED VACCINE THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA
https://doi.org/10.17650/1726-9776-2010-6-2-22-31
Abstract
Objective: to study the efficiency and tolerance of autologous vaccine therapy based on dendritic cells (DC) in patients with renal cell carcinoma (RCC) and to examine changes in immunological parameters and their association with the efficiency of the therapy. Subjects and methods. Twenty-nine patients with RCC received autologous vaccine therapy based on DC in 2002 to 2008. Therapy was performed in the induction mode in 16 patients before disease progression and in the adjuvant mode (8 vaccinations) in 13 patients after radical nephrectomy (grade III) or radical metastasectomy. Peripheral blood monocyte-derived DCs treated with autologous tumor lysate were used to prepare the vaccine. Results. In a group of 16 patients with distant metastases, partial regressions were recorded in 2 (12.5%) patients and long (> 6-month) stabilizations of a tumor process were observed in other 2 (12.5%) patients. The median time prior to progression was 3 (range 1.5-12) months. Thirteen patients on adjuvant treatment did not achieve the median time to progression: 4 patients showed no signs of disease progression ?12 to ?25 months after metastasectomy. Patients with a clinical effect (disease regression or long stabilization) showed a significant increase in the populations of CD3+CD8+ and CD3-CD16+ T lymphocytes (natural killers (NK) cells) after 3 vaccinations from 23.3 to 27.2% (p = 0.018) and from 15.17 to 20.3%, respectively (p = 0.03). Prior to vaccine therapy, the count of CD3+CD16+-NK cells was thrice greater in patients with the progressive disease than that in the donor group - 11.2 and 3.5%, respectively. The baseline count of CD4+CD25+ Т lymphocytes in patients with progressive disease was also significantly higher than that in patients with the clinical effect - 12.01 and 5.6%, respectively. Conclusion. In patients with RCC, DC-based vaccine therapy is able to induce a specific anti-tumor immune response that is transformed into the clinical effect in some cases. The baseline count of suppressor T lymphocyte (NKT and T-reg) populations may be a factor that predicts the efficiency of autologous DC-based vaccine therapy in patients with RCC. This immunotherapeutic approach merits further study, by defining the indications for its application in patients with RCC.
About the Authors
D. A. Nosov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
A. A. Borunova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
G. Z. Chkadua
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
V. B. Matveyev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
E. S. Yakovleva
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
M. Yu. Fedyanin
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
Z. G. Kadagidze
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
T. N. Zabotina
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
S. A. Tyulyandin
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Oliver R.T.D. Unexplained spontaneous regression and its relevance to the clinical behavior of renal cell carcinoma and its response to interferon, abstract 383. Proc Am Soc Clin Oncol 1987;6:98.
2. Bukowski R.M. Natural history and therapy of metastatic renal cell carcinoma. The role of interleukin-2. Cancer 1997;80:1198-220.
3. Motzer R.J., Masumdar M., Bacic J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8):2530-40.
4. Motzer R.J., Bacik J., Murphy B.A. et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(1):289-96.
5. Messing E.M., Manola J., Wilding G. et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An Eastern Cooperative Oncology Group/Intergroup Trial. J Clin Oncol 2003;21(7):1214-22.
6. Atzpodien J., Schmitt E., Gertenbach U. Adjuvant treatment with interleukin-2-and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2005;92(5):843-6.
7. Clark J., Atkins M., Urba W. et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk RCC: A Cytokine Working group randomized trial. J Clin Oncol 2003;21(16):3133-40.
8. Jocham D., Richter A., Hoffmann L. et al. Adjuvant autologous renal tumor cell vaccine and risk of tumor progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363:594-9.
9. Schärfe T., Müller S., Riedmiller H. et al. Immunotherapy of metastasizing renal cell carcinoma. Results of a multicentered trial. Urol Int 1989;44:1-4.
10. Galligioni E., Quaia M., Merlo A. et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: 5-year results of a prospective randomized study. Cancer 1996;77:2560-6.
11. Schwaab T., Heaney J.A., Schned A.R. et al. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J Urol 2000;163:1322-7.
12. Steinman R.M. The dendritic cells system and its role in immunogenecity. Ann Rev Immun 1991;9:271-96.
13. Mulders P., Tso C.L., Gitlitz B. et al. Presentation of renal tumor antigens by human dendritic cells activates tumorinfiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin Cancer Res 1999;5:445-54.
14. Thurnher M., Radmayr C., Ramoner R. et al. Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer 1996;68:1-7.
15. Troy A.J., Summers K.L., Davidson P.J.T. et al. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 1998;4:585-93.
16. Knoefel B., Nuske K., Steiner T. et al. Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-beta 1 in primary cultures and modulate T lymphocyte blast transformation. J Interfer Cytok Res 1997;17:95-102.
17. Chaux P., Favre N., Martin M. et al. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int J Cancer 1997;72:619-24.
18. Jiang H., Chess L. An integrated view of suppressor T cells subsets in immunoregulation. J Clin Investig 2004;114(9):1198-208.
19. Thronton A.M., Picirillo C.A.,Shevach E.M. Activation requirements for the induction of CD4+CD25+ T cell suppressor function. Eur J Immunol 2004;24:366-73.
20. Mars L.T., Novak J., Liblau R.S.,Lehuen A. Terapeutic manipulation of iНКT cells in autoimmunity: modes of action and risks. Tends Immunol 2004;25:471-82.
21. Terabe M., Matsui S., Park J.M. et al. Transforming growth factor-production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocytemediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003;198:1741-50.
22. Кадагидзе З.Г., Черткова А.И.,Славина Е.Г. Иммунорегуляторные CD25+CD4+-клетки. Биотер журн 2005;(2):13-21.
23. Kugler A., Stuhler G., Walden P. et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell dendritic cell hybrids. Nat Med 2000;6:332-6.
24. Nestle F.O., Alijagic S., Gilliet M. et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
25. Holtl L., Zelle-Rieser C., Gander H. et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002;8:3369-76.
26. Wierecky J., Muller M.R., Wirths S. et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006;66:11.
27. Marten A., Flieger D., Renoth S. et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother 2002;51:637-44.
28. Gitlitz B., Belldegrun A., Zisman A. et al. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother 2003;26(5):412-9.
29. Motzer R., Thomas M., Hutson E. et al. Sunitinib versus interferon Alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
30. Escudier B., Eisen T, Stadler W. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
31. Escudier B., Koralewski P., Pluzanska A. et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-2-a vs placebo/interferon-2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol 2007;25:2(suppl; abstr 3).
32. Борунова А.А., Чкадуа Г.З.,Заботина Т.Н. Перфорин-опосредованная цитотоксичность CD16+-лимфоцитов. Иммунология 2006;(1):4-6.
33. Борунова А.А., Чкадуа Г.З.,Заботина Т.Н., Кадагидзе З.Г. Перфориновый потенциал эффекторных клеток у он-кологических больных при вакцинотера-пии. Вестн ГУ РОНЦ им. Н.Н. Блохина РАМН 2005;(3-4):7-9.
34. Sakaguchi S. Naturally arising FoxP3-expressing CD25+CD4+ regulatory T cells in immunologycal tolerance to self and non-self. Nat Immunol 2005;6:345-52.
35. Yu P., Lee Y., Liu W. et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of latestage tumors. J Exp Med 2005;201:779-91.
36. Ярилин А.А., Донецкова Д.Д. Естественные регуляторные Т-клетки и фактор FOXP. Иммунология 2006;(3):176-88.
37. Zisman A., Pantuck A., Dorey F. et al. Improved prognostication of renal cell carcinoma usingan integrated staging system. J Clin Oncol 2001;19:1649-57.
38. Чкадуа Г.З., Заботина Т.Н.,Буркова А.А. и др. Адаптирование мето-дики культивирования дендритных клеток человека из моноцитов периферической крови для клинического применения. Рос биотер журн 2002;(3):56-62.
Review
For citations:
Nosov D.A., Borunova A.A., Chkadua G.Z., Matveyev V.B., Yakovleva E.S., Fedyanin M.Yu., Kadagidze Z.G., Zabotina T.N., Tyulyandin S.A. DENDRITIC CELL-BASED VACCINE THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA. Cancer Urology. 2010;6(2):22-31. (In Russ.) https://doi.org/10.17650/1726-9776-2010-6-2-22-31
Views:
1131
Email this article 